Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance resultsNorio Hanafusa, Michio Kato, Tomoaki Ishihara et al.|PLoS ONE|2017Cited by 56
Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodiesTetsuya Inoue, Kohji Noguchi|iScience|2024Cited by 11
Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodiesTetsuya Inoue, Kohji Noguchi|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 1